These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 20404746)

  • 1. Improvement of bilateral ptosis on higher dose enzyme replacement therapy in Pompe disease.
    Yanovitch TL; Casey R; Banugaria SG; Kishnani PS
    J Neuroophthalmol; 2010 Jun; 30(2):165-6. PubMed ID: 20404746
    [No Abstract]   [Full Text] [Related]  

  • 2. Ptosis in Pompe disease: common genetic background in infantile and adult series.
    Ravaglia S; Bini P; Garaghani KS; Danesino C
    J Neuroophthalmol; 2010 Dec; 30(4):389-90. PubMed ID: 21107130
    [No Abstract]   [Full Text] [Related]  

  • 3. Enzyme replacement therapy in classical infantile pompe disease: results of a ten-month follow-up study.
    Klinge L; Straub V; Neudorf U; Voit T
    Neuropediatrics; 2005 Feb; 36(1):6-11. PubMed ID: 15776317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyaluronidase increases the biodistribution of acid alpha-1,4 glucosidase in the muscle of Pompe disease mice: an approach to enhance the efficacy of enzyme replacement therapy.
    Matalon R; Surendran S; Campbell GA; Michals-Matalon K; Tyring SK; Grady J; Cheng S; Kaye E
    Biochem Biophys Res Commun; 2006 Nov; 350(3):783-7. PubMed ID: 17027913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of the muscle volume analyzer to evaluate enzyme replacement therapy in late-onset Pompe disease.
    Sugai F; Kokunai Y; Yamamoto Y; Hashida G; Shimazu K; Mihara M; Inoue S; Sakoda S
    J Neurol; 2010 Mar; 257(3):461-3. PubMed ID: 19908083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-frequency enzyme replacement therapy in late-onset Pompe disease.
    Lin DS; Chiang MF; Ho CS; Hsiao CD; Lin CY; Wang NL; Chuang CK; Huang YW; Chang PC; Liu HL
    Muscle Nerve; 2013 Apr; 47(4):612-3. PubMed ID: 23322609
    [No Abstract]   [Full Text] [Related]  

  • 7. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study.
    van der Ploeg A; Carlier PG; Carlier RY; Kissel JT; Schoser B; Wenninger S; Pestronk A; Barohn RJ; Dimachkie MM; Goker-Alpan O; Mozaffar T; Pena LD; Simmons Z; Straub V; Guglieri M; Young P; Boentert M; Baudin PY; Wens S; Shafi R; Bjartmar C; Thurberg BL
    Mol Genet Metab; 2016 Sep; 119(1-2):115-23. PubMed ID: 27473031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical and electrodiagnostic characteristics of Pompe disease with post-enzyme replacement therapy findings.
    Hobson-Webb LD; Dearmey S; Kishnani PS
    Clin Neurophysiol; 2011 Nov; 122(11):2312-7. PubMed ID: 21570905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme replacement therapy for infantile-onset pompe disease: curse or cure?
    Willems J; Petros A; Brierley J
    Neurology; 2008 Jul; 71(5):380-1. PubMed ID: 18663187
    [No Abstract]   [Full Text] [Related]  

  • 10. Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up.
    Winkel LP; Van den Hout JM; Kamphoven JH; Disseldorp JA; Remmerswaal M; Arts WF; Loonen MC; Vulto AG; Van Doorn PA; De Jong G; Hop W; Smit GP; Shapira SK; Boer MA; van Diggelen OP; Reuser AJ; Van der Ploeg AT
    Ann Neurol; 2004 Apr; 55(4):495-502. PubMed ID: 15048888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy.
    Winkel LP; Kamphoven JH; van den Hout HJ; Severijnen LA; van Doorn PA; Reuser AJ; van der Ploeg AT
    Muscle Nerve; 2003 Jun; 27(6):743-51. PubMed ID: 12766987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infantile Pompe disease: clinical and genetic characteristics with an experience of enzyme replacement therapy.
    Cho A; Kim SJ; Lim BC; Hwang H; Park JD; Kim GB; Jin DK; Lee J; Ki CS; Kim KJ; Hwang YS; Chae JH
    J Child Neurol; 2012 Mar; 27(3):319-24. PubMed ID: 21940687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adult Pompe disease: clinical manifestations and outcome of the first Greek patients receiving enzyme replacement therapy.
    Papadimas GK; Spengos K; Konstantinopoulou A; Vassilopoulou S; Vontzalidis A; Papadopoulos C; Michelakakis H; Manta P
    Clin Neurol Neurosurg; 2011 May; 113(4):303-7. PubMed ID: 21216089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term enzyme-replacement therapy (ERT) with alglucosidase alfa: Evolution of two siblings with juvenile late-onset Pompe disease.
    Rafael Bretón Martínez J; Martínez AC
    J Neurol Sci; 2015 Nov; 358(1-2):459-60. PubMed ID: 26279333
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial.
    Klinge L; Straub V; Neudorf U; Schaper J; Bosbach T; Görlinger K; Wallot M; Richards S; Voit T
    Neuromuscul Disord; 2005 Jan; 15(1):24-31. PubMed ID: 15639117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 24-months results in two adults with Pompe disease on enzyme replacement therapy.
    Vielhaber S; Brejova A; Debska-Vielhaber G; Kaufmann J; Feistner H; Schoenfeld MA; Awiszus F
    Clin Neurol Neurosurg; 2011 Jun; 113(5):350-7. PubMed ID: 21477922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sixty six-month follow-up of muscle power and respiratory function in a case with adult-type Pompe disease treated with enzyme replacement therapy.
    Isayama R; Shiga K; Seo K; Azuma Y; Araki Y; Hamano A; Takezawa H; Kuriyama N; Takezawa N; Mizuno T; Nakagawa M
    J Clin Neuromuscul Dis; 2014 Jun; 15(4):152-6. PubMed ID: 24872213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Making diagnosis of Pompe disease at a presymptomatic stage: to treat or not to treat?
    Laloui K; Wary C; Carlier RY; Hogrel JY; Caillaud C; Laforêt P
    Neurology; 2011 Aug; 77(6):594-5. PubMed ID: 21753173
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail.
    Kikuchi T; Yang HW; Pennybacker M; Ichihara N; Mizutani M; Van Hove JL; Chen YT
    J Clin Invest; 1998 Feb; 101(4):827-33. PubMed ID: 9466978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.
    Raben N; Fukuda T; Gilbert AL; de Jong D; Thurberg BL; Mattaliano RJ; Meikle P; Hopwood JJ; Nagashima K; Nagaraju K; Plotz PH
    Mol Ther; 2005 Jan; 11(1):48-56. PubMed ID: 15585405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.